Drug Trial Radar · NCT02063659
Telotristat Etiprate for Carcinoid Syndrome Therapy
Last checked: Nov 20, 2026Latest source record: Feb 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Mar 11, 2014
Primary completion
Mar 29, 2016
Study completion Mar 29, 2016
Sponsor
- Lead sponsor
- Lexicon PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 14, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.
Conditions
- Carcinoid Syndrome
Interventions
Telotristat etiprateDrug
Telotristat etiprate tablets
PlaceboDrug
Placebo-matching telotristat etiprate tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment PeriodTime frame: First dose of study drug to within 30 days of last dose of study drug in the Double-Blind Treatment Period (Up to 17.1 Weeks)
- Primary: Percent Change From Baseline in Urinary 5-hydroxyindoleacetic Acid (u5-HIAA) LevelsTime frame: Baseline and 12 Weeks
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Open-Label Extension PeriodTime frame: First dose of study drug to within 30 days of last dose of study drug in the Open-Label Extension Period (Up to 52.6 Weeks)
Locations
50 sites in 11 countries. Site status is shown where the registry gives one.
Lexicon Investigational Site
Stanford, California
Lexicon Investigational Site
Orlando, Florida
Lexicon Investigational Site
Iowa City, Iowa
Lexicon Investigational Site
Lexington, Kentucky
Lexicon Investigational Site
Boston, Massachusetts
Lexicon Investigational Site
Buffalo, New York
Lexicon Investigational Site
New York, New York
Lexicon Investigational Site
Philadelphia, Pennsylvania
Lexicon Investigational Site
Kogara, New South Wales, Australia
Lexicon Investigational Site
St Leonards, New South Wales, Australia
Lexicon Investigational Site
Herston, Queensland, Australia
Lexicon Investigational Site
East Melbourne, Victoria, Australia
Lexicon Investigational Site
Edegem, Belgium
Lexicon Investigational Site
Ghent, Belgium
Lexicon Investigational Site
Yvoir, Belgium
Lexicon Investigational Site
Calgary, Alberta, Canada
Lexicon Investigational Site
Halifax, Nova Scotia, Canada
Lexicon Investigational Site
Clichy, France
Lexicon Investigational Site
Lille, France
Lexicon Investigational Site
Lyon, France
Lexicon Investigational Site
Marseille, France
Lexicon Investigational Site
Strasbourg, France
Lexicon Investigational Site
Villejuif, France
Lexicon Investigational Site
Bad Berka, Germany
Lexicon Investigational Site
Berlin, Germany
Lexicon Investigational Site
Hamburg, Germany
Lexicon Investigational Site
Heidelberg, Germany
Lexicon Investigational Site
Lübeck, Germany
Lexicon Investigational Site
Mainz, Germany
Lexicon Investigational Site
Marburg, Germany
Lexicon Investigational Site
Munich, Germany
Lexicon Investigational Site
Neuss, Germany
Lexicon Investigational Site
Jerusalem, Israel
Lexicon Investigational Site
Noord Brahant, Netherlands
Lexicon Investigative Site
Rotterdam, Netherlands
Lexicon Investigational Site
Amsterdam, North Holland, Netherlands
Lexicon Investigational Site
Amsterdam, North Holland, Netherlands
Lexicon Investigational Site
Barcelona, Spain
Lexicon Investigational Site
Barcelona, Spain
Lexicon Investigational Site
Madrid, Spain
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.